Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Accumulated Expenses (2020 - 2025)

Arcutis Biotherapeutics has reported Accumulated Expenses over the past 6 years, most recently at $116.3 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $116.3 million for Q4 2025, up 74.14% from a year ago — trailing twelve months through Dec 2025 was $116.3 million (up 74.14% YoY), and the annual figure for FY2025 was $116.3 million, up 74.14%.
  • Accumulated Expenses for Q4 2025 was $116.3 million at Arcutis Biotherapeutics, up from $93.0 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for ARQT hit a ceiling of $116.3 million in Q4 2025 and a floor of $10.6 million in Q2 2021.
  • Median Accumulated Expenses over the past 5 years was $28.2 million (2022), compared with a mean of $41.0 million.
  • Biggest five-year swings in Accumulated Expenses: dropped 13.69% in 2021 and later soared 126.67% in 2024.
  • Arcutis Biotherapeutics' Accumulated Expenses stood at $25.5 million in 2021, then increased by 10.9% to $28.3 million in 2022, then rose by 19.84% to $33.9 million in 2023, then soared by 96.79% to $66.8 million in 2024, then surged by 74.14% to $116.3 million in 2025.
  • The last three reported values for Accumulated Expenses were $116.3 million (Q4 2025), $93.0 million (Q3 2025), and $87.9 million (Q2 2025) per Business Quant data.